ArticleAntimicrobial agents and chemotherapy2026
Efficacy and safety of doravirine/lamivudine/tenofovir as initial treatment for people living with HIV in China.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The newly approved oral anti-HIV doravirine (DOR)-based regimen in China in treatment-naïve people living with HIV (PLWH) remains inadequately characterized in China, particularly regarding antiviral efficacy and lipid profile changes. This study aimed to assess 48-week antiviral effectiveness and lipid changes associated with a DOR-based regimen in treatment-naïve PLWH compared with other regimens. A real-world retrospective study was conducted involving treatment-naïve PLWH who initiated DOR/TDF/3TC, EFV/TDF/3TC, DTG/TDF/3TC, or BIC/TAF/FTC. At week 48, 96.22% of participants receiving DOR/TDF/3TC achieved viral suppression, accompanied by significant increases in CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.